Stock 2480 BEIJING LUZHU BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Beijing Luzhu Biotechnology Co., Ltd.

Equities

2480

CNE100005YD8

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:28 2024-05-24 EDT 		5-day change 1st Jan Change
23.9 HKD -1.65% Intraday chart for Beijing Luzhu Biotechnology Co., Ltd. -4.02% -20.07%
05-07 59,729,296 Domestic Shares of Beijing Luzhu Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-MAY-2024. CI
05-07 132,333,736 H Shares of Beijing Luzhu Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-MAY-2024. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
59,729,296 Domestic Shares of Beijing Luzhu Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.
CI
132,333,736 H Shares of Beijing Luzhu Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.
CI
Beijing Luzhu Biotechnology Posts Lower Loss in 2023 Amid Higher Other Income
MT
Beijing Luzhu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Luzhu Biotechnology Completes H Share Full Circulation
MT
Luzhu Biotechnology Gets Hong Kong Bourse's Nod to List Converted Shares
MT
Beijing Luzhu Biotechnology Completes Patient Enrollment for Phase 3 Trial for Shingles
MT
Luzhu Biotech Completes Enrollment of Subjects for Phase III Trial of Shingles Vaccine in China
MT
Beijing Luzhu Biotechnology Co., Ltd. Announces the Completion of Enrollment of Subjects for Phase III Clinical Trial of LZ901 in the PRC
CI
4,786,400 H Shares of Beijing Luzhu Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-NOV-2023.
CI
Luzhu Biotechnology Begins Phase III Clinical Trial of Shingles Drug
MT
Beijing Luzhu Biotechnology Co., Ltd. Announces Initiation of Phase III Clinical Trial and Completion of Enrollment of First Group of Subjects for LZ901 in the PRC
CI
Beijing Luzhu Biotechnology Co., Ltd.(SEHK:2480) added to S&P Global BMI Index
CI
Beijing Luzhu Biotechnology Slashes H1 Loss
MT
Beijing Luzhu Biotechnology to Shrink H1 Loss by 87%
MT
Beijing Luzhu Biotechnology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023
CI
Luzhu Biotechnology Ties Up With Tianjin Ringpu to Develop Pet Vaccines, Drugs
MT
Beijing Luzhu Biotechnology Co., Ltd. and Tianjin Ringpu Bio-Technology Co., Ltd. Announces Strategic Cooperation Framework Agreement
CI
Luzhu Biotechnology CFO Steps Down
MT
Beijing Luzhu Biotechnology Co., Ltd. Announces Change in Chief Executive Officer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2480 Stock
  4. News Beijing Luzhu Biotechnology Co., Ltd.